The FDA has approved the first permanent implant to relieve low or blocked urine flow in men aged 50 years and older with benign prostatic hyperplasia (BPH).

Manufactured by NeoTract, the UroLift System relieves urine flow by pulling back prostate tissue pressing on the urethra.

The FDA describes the device as a less invasive alternative to surgery for BPH treatment and an option for men who cannot tolerate available drug therapies.

Continue Reading